These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35980242)

  • 1. Glucose and lipid metabolism abnormalities in Cushing's syndrome.
    Salehidoost R; Korbonits M
    J Neuroendocrinol; 2022 Aug; 34(8):e13143. PubMed ID: 35980242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic comorbidities in Cushing's syndrome.
    Ferraù F; Korbonits M
    Eur J Endocrinol; 2015 Oct; 173(4):M133-57. PubMed ID: 26060052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Syndrome in Cushing's Syndrome Patients.
    Ferraù F; Korbonits M
    Front Horm Res; 2018; 49():85-103. PubMed ID: 29894989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiology of diabetes mellitus in Cushing's syndrome.
    Pivonello R; De Leo M; Vitale P; Cozzolino A; Simeoli C; De Martino MC; Lombardi G; Colao A
    Neuroendocrinology; 2010; 92 Suppl 1():77-81. PubMed ID: 20829623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity.
    Lee MJ; Pramyothin P; Karastergiou K; Fried SK
    Biochim Biophys Acta; 2014 Mar; 1842(3):473-81. PubMed ID: 23735216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoid-induced insulin resistance is related to macrophage visceral adipose tissue infiltration.
    Do TTH; Marie G; Héloïse D; Guillaume D; Marthe M; Bruno F; Marion B
    J Steroid Biochem Mol Biol; 2019 Jan; 185():150-162. PubMed ID: 30145227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology of dyslipidemia in Cushing's syndrome.
    Arnaldi G; Scandali VM; Trementino L; Cardinaletti M; Appolloni G; Boscaro M
    Neuroendocrinology; 2010; 92 Suppl 1():86-90. PubMed ID: 20829625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in adenosine 5'-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome.
    Kola B; Christ-Crain M; Lolli F; Arnaldi G; Giacchetti G; Boscaro M; Grossman AB; Korbonits M
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4969-73. PubMed ID: 18782871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose metabolism in Cushing's syndrome.
    Sharma A; Vella A
    Curr Opin Endocrinol Diabetes Obes; 2020 Jun; 27(3):140-145. PubMed ID: 32250974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal Stem Cells Exposed to Persistently High Glucocorticoid Levels Develop Insulin-Resistance and Altered Lipolysis: A Promising
    Di Vincenzo M; Martino M; Lariccia V; Giancola G; Licini C; Di Benedetto G; Arnaldi G; Orciani M
    Front Endocrinol (Lausanne); 2022; 13():816229. PubMed ID: 35282448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation among body composition and metabolic regulation in a male mouse model of Cushing's syndrome.
    Uehara M; Yamazaki H; Yoshikawa N; Kuribara-Souta A; Tanaka H
    Endocr J; 2020 Jan; 67(1):21-30. PubMed ID: 31495810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of leptin levels in plasma and their reliance on other hormonal factors affecting tissue fat levels in people with various levels of endogenous cotisol].
    Robaczyk MG
    Ann Acad Med Stetin; 2002; 48():283-300. PubMed ID: 14601484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adipose tissue in cortisol excess: What Cushing's syndrome can teach us?
    Bavaresco A; Mazzeo P; Lazzara M; Barbot M
    Biochem Pharmacol; 2024 May; 223():116137. PubMed ID: 38494065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Mechanisms of Glucocorticoid-Induced Insulin Resistance.
    Beaupere C; Liboz A; Fève B; Blondeau B; Guillemain G
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MECHANISMS IN ENDOCRINOLOGY: Tissue-specific activation of cortisol in Cushing's syndrome.
    Morgan SA; Hassan-Smith ZK; Lavery GG
    Eur J Endocrinol; 2016 Aug; 175(2):R83-9. PubMed ID: 26957494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic hypercortisolism causes more persistent visceral adiposity than HFD-induced obesity.
    García-Eguren G; Giró O; Romero MDM; Grasa M; Hanzu FA
    J Endocrinol; 2019 Aug; 242(2):65-77. PubMed ID: 31117053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose metabolism in patients with subclinical Cushing's syndrome.
    Giordano R; Guaraldi F; Berardelli R; Karamouzis I; D'Angelo V; Marinazzo E; Picu A; Ghigo E; Arvat E
    Endocrine; 2012 Jun; 41(3):415-23. PubMed ID: 22391939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cushing's syndrome, glucocorticoids and the kidney.
    Smets P; Meyer E; Maddens B; Daminet S
    Gen Comp Endocrinol; 2010 Oct; 169(1):1-10. PubMed ID: 20655918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism.
    Geer EB; Islam J; Buettner C
    Endocrinol Metab Clin North Am; 2014 Mar; 43(1):75-102. PubMed ID: 24582093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.